Bioxodes SA
@bioxodes.com
Bioxodes is developing a novel drug candidate, Ir-CPI, for hemorrhagic stroke patients.
Bioxodes SA's Company Logos
Bioxodes SA's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#95979C
Manatee
149, 151, 156
223, 3, 60
4, 3, 0, 39
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#010101
Black
1, 1, 1
0, 0, 0
0, 0, 0, 100
About Bioxodes SA
Bioxodes SA is a clinical-stage biopharmaceutical company that specializes in the development of innovative drug candidates. Their main focus is on creating a first-in-class drug candidate called Ir-CPI, which aims to prevent thrombosis and neuroinflammation in hemorrhagic stroke patients. By targeting coagulation factors and neutrophils, key components of neuroinflammatory and thrombotic processes, Ir-CPI offers a unique mechanism of action.
Bioxodes has successfully completed the active phase of its First-in-Human study on healthy adult volunteers with Ir-CPI. They are also developing a pipeline of drug candidates that target chronic thrombo-inflammatory and inflammatory diseases. Located in the Brussels South Charleroi Biopark in Belgium, Bioxodes boasts a team of experienced professionals, including Dr.
Edmond Godfroid, the company's Managing Director, who has a strong background in molecular biology and pharmacologically active proteins. With a dedication to innovation and scientific advancement, Bioxodes is making significant strides in revolutionizing the treatment of thrombosis and neuroinflammation
Company type
Privately Held
Year founded
2013
Company size
2-10 employees
